CY1120821T1 - Παραγωγα ταμοξιφαινης για θεραπεια νεοπλασματικων ασθενειων, ειδικα με υψηλο επιπεδο πρωτεϊνης her2 - Google Patents
Παραγωγα ταμοξιφαινης για θεραπεια νεοπλασματικων ασθενειων, ειδικα με υψηλο επιπεδο πρωτεϊνης her2Info
- Publication number
- CY1120821T1 CY1120821T1 CY181101155T CY181101155T CY1120821T1 CY 1120821 T1 CY1120821 T1 CY 1120821T1 CY 181101155 T CY181101155 T CY 181101155T CY 181101155 T CY181101155 T CY 181101155T CY 1120821 T1 CY1120821 T1 CY 1120821T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- general formula
- her2 protein
- aliphatic
- tamoxifaine
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract 2
- -1 aliphatic triphenylphosphonate derivatives Chemical class 0.000 abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Natural products C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- 150000004820 halides Chemical class 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 229960001603 tamoxifen Drugs 0.000 abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940072107 ascorbate Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5456—Arylalkanephosphonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5449—Polyphosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
- C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/14—Styryl dyes
- C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B69/00—Dyes not provided for by a single group of this subclass
- C09B69/008—Dyes containing a substituent, which contains a silicium atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
Abstract
Το αντικείμενο της εφεύρεσης είναι νέα μιτοχονδριακά στοχευόμενα Ε/Ζ ισομερή των αλειφατικών τριφαινυλοφωσφόνιων παραγώγων της ταμοξιφαίνης, όπου η αλειφατική αλυσίδα είναι αλκύλιο ή αλκενύλιο και τα αντίστοιχα άλατα της τριτοταγούς αμίνης που επιλέγονται από οργανικά άλατα όπως κιτρικό, γαλακτικό, τρυγικό, οξαλικό, ασκορβικό, μεσυλικό, τοσυλικό ή ανόργανα άλατα όπως π.χ. θειικό, αλογονίδιο ή φωσφορικό ή/και το μείγμα τους (Mito TAX) που έχουν το γενικό τύπο I, όπου το n = 8 έως 12 και το Ζ επιλέγεται από οργανικά άλατα όπως κιτρικό, οξικό, γαλακτικό, τρυγικό, οξαλικό, ασκορβικό, μεσυλικό, τοσυλικό ή ανόργανα άλατα όπως θειικό, αλογονίδιο, φωσφορικό και έχουν γενικό τύπο ΙΑ, όπου n = 6 έως 10 και το Ζ έχει την προαναφερθείσα σημασία. Μπορούν να χρησιμοποιηθούν για θεραπεία νεπλασματικών ασθενειών, ειδικά με υψηλό επίπεδο της πρωτεΐνης HER2. Το φάρμακο για θεραπεία νεοπλασματιών ασθενειών, σύμφωνα με την εφεύρεση, περιέχει τουλάχιστον ένα Ε/Ζ ισομερές των αλειφατικών τριφαινυλοφωσφόνιων παραγώγων της ταμοξιφαίνης με γενικό τύπο I ή/και ΙΑ ή του αντίστοιχου άλατος της τριτοταγούς αμίνης.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2013-308A CZ2013308A3 (cs) | 2013-04-24 | 2013-04-24 | Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2 |
| CZ2014-66A CZ305571B6 (cs) | 2014-01-29 | 2014-01-29 | Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2 |
| PCT/CZ2014/000035 WO2014173374A1 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120821T1 true CY1120821T1 (el) | 2019-12-11 |
Family
ID=50677895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181101155T CY1120821T1 (el) | 2013-04-24 | 2018-11-06 | Παραγωγα ταμοξιφαινης για θεραπεια νεοπλασματικων ασθενειων, ειδικα με υψηλο επιπεδο πρωτεϊνης her2 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9896466B2 (el) |
| EP (1) | EP2989110B1 (el) |
| JP (1) | JP6375091B2 (el) |
| KR (1) | KR101764991B1 (el) |
| CN (1) | CN105452265B (el) |
| AU (1) | AU2014256546B2 (el) |
| CA (1) | CA2909994C (el) |
| CY (1) | CY1120821T1 (el) |
| DK (1) | DK2989110T3 (el) |
| EA (1) | EA029881B1 (el) |
| ES (1) | ES2699099T3 (el) |
| GE (1) | GEP20186868B (el) |
| HK (1) | HK1216317A1 (el) |
| HR (1) | HRP20181872T1 (el) |
| HU (1) | HUE042239T2 (el) |
| MD (1) | MD4626C1 (el) |
| NZ (1) | NZ713589A (el) |
| PL (1) | PL2989110T3 (el) |
| PT (1) | PT2989110T (el) |
| SI (1) | SI2989110T1 (el) |
| UA (1) | UA116469C2 (el) |
| WO (1) | WO2014173374A1 (el) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018000295A (es) * | 2015-07-03 | 2018-03-08 | Bayer Cropscience Ag | Derivados de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida con accion herbicida. |
| PL3317272T3 (pl) * | 2015-07-03 | 2020-01-31 | Bayer Cropscience Aktiengesellschaft | Chwastobójczo skuteczne pochodne N-(1,3,4-oksadiazol-2-ilo)arylokarboksyamidowe |
| JP2019525955A (ja) * | 2016-07-12 | 2019-09-12 | アキュター バイオテクノロジー インコーポレイテッド | 新規化合物およびその使用 |
| JP7100019B2 (ja) | 2016-08-19 | 2022-07-12 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する |
| EP3330274A1 (en) * | 2016-12-01 | 2018-06-06 | Springtide Ventures s.r.o. | Compounds for treatment of senescence-related disorders |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| CA3060509A1 (en) | 2017-04-21 | 2018-10-25 | Federica Sotgia | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| CR20190524A (es) | 2017-05-19 | 2020-01-10 | Lunella Biotech Inc | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas |
| CR20200218A (es) | 2017-10-24 | 2020-12-23 | Lunella Biotech Inc | Mitoflavoscinas: la fijaciòn como objetivo de enzimas que contienen flavina elimina cèlulas madre cancerosas (cscs) al inhibir la respiraciòn mitocondrial |
| CA3083023A1 (en) | 2017-11-24 | 2019-05-31 | Lunella Biotech, Inc. | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
| US11497759B2 (en) | 2017-12-01 | 2022-11-15 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| WO2019113210A1 (en) | 2017-12-05 | 2019-06-13 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
| EP3728300A4 (en) | 2017-12-20 | 2021-08-11 | Lunella Biotech, Inc. | TARGETING MITOCHONDRIAL FISSION VIA MDIVI-1 DERIVATIVES |
| US20220211728A1 (en) * | 2019-04-16 | 2022-07-07 | Lunella Biotech, Inc. | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments |
| EP3753944A1 (en) | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1289570C (en) * | 1986-06-16 | 1991-09-24 | Tetsuji Asao | 1,1,2-triaryl-1-alkene derivatives |
| CA2092996A1 (en) * | 1990-10-01 | 1992-04-02 | David Yang | High affinity tamoxifen derivatives and uses thereof |
| JP3635708B2 (ja) * | 1995-03-06 | 2005-04-06 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| TWI309571B (en) * | 2002-12-31 | 2009-05-11 | Ind Tech Res Inst | Delivery carrier for targeting cells haring over-expressed estrogen |
| NZ546070A (en) * | 2003-08-22 | 2010-01-29 | Antipodean Pharmaceuticals Inc | Mitoquinone derivatives used as mitochondrially targeted antioxidants |
| RU2007105138A (ru) * | 2004-07-13 | 2008-08-20 | Оридис Биомед Форшунгс-Унд Энтвиклунгс Гмбх (At) | Применение митохондриально направленного антиоксиданта при лечении болезней печени и эпителиальных раковых опухолей |
| JP5616798B2 (ja) * | 2008-03-14 | 2014-10-29 | スティーブン・ジョン・ラルフＳｔｅｐｈｅｎ Ｊｏｈｎ ＲＡＬＰＨ | ミトコンドリア由来の抗ガン化合物 |
| MX2011010956A (es) * | 2009-04-17 | 2012-01-27 | Colby Pharmaceutical Company | Composiciones farmaceuticamente activas que comprenden moduladores de estres oxidativo (osm por sus siglas en inglés), nuevas entidades quimicas, composiciones y usos. |
| WO2011129837A1 (en) * | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
-
2014
- 2014-04-07 CN CN201480033316.9A patent/CN105452265B/zh active Active
- 2014-04-07 ES ES14721738T patent/ES2699099T3/es active Active
- 2014-04-07 CA CA2909994A patent/CA2909994C/en active Active
- 2014-04-07 PL PL14721738T patent/PL2989110T3/pl unknown
- 2014-04-07 JP JP2016509298A patent/JP6375091B2/ja active Active
- 2014-04-07 US US14/786,710 patent/US9896466B2/en active Active
- 2014-04-07 KR KR1020157030376A patent/KR101764991B1/ko active IP Right Grant
- 2014-04-07 SI SI201430928T patent/SI2989110T1/sl unknown
- 2014-04-07 NZ NZ713589A patent/NZ713589A/en unknown
- 2014-04-07 UA UAA201510642A patent/UA116469C2/uk unknown
- 2014-04-07 HU HUE14721738A patent/HUE042239T2/hu unknown
- 2014-04-07 PT PT14721738T patent/PT2989110T/pt unknown
- 2014-04-07 EA EA201591918A patent/EA029881B1/ru unknown
- 2014-04-07 WO PCT/CZ2014/000035 patent/WO2014173374A1/en active Application Filing
- 2014-04-07 EP EP14721738.4A patent/EP2989110B1/en active Active
- 2014-04-07 DK DK14721738.4T patent/DK2989110T3/en active
- 2014-04-07 AU AU2014256546A patent/AU2014256546B2/en not_active Ceased
- 2014-04-07 MD MD20150117A patent/MD4626C1/ro active IP Right Grant
-
2015
- 2015-04-07 GE GEAP201513996A patent/GEP20186868B/en unknown
-
2016
- 2016-04-14 HK HK16104277.8A patent/HK1216317A1/zh unknown
-
2018
- 2018-11-06 CY CY181101155T patent/CY1120821T1/el unknown
- 2018-11-08 HR HRP20181872TT patent/HRP20181872T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014256546B2 (en) | 2017-03-30 |
| US20160075726A1 (en) | 2016-03-17 |
| ES2699099T3 (es) | 2019-02-07 |
| KR101764991B1 (ko) | 2017-08-10 |
| HUE042239T2 (hu) | 2019-06-28 |
| JP6375091B2 (ja) | 2018-08-15 |
| CN105452265A (zh) | 2016-03-30 |
| EA029881B1 (ru) | 2018-05-31 |
| JP2016522179A (ja) | 2016-07-28 |
| MD4626C1 (ro) | 2019-11-30 |
| MD4626B1 (ro) | 2019-04-30 |
| NZ713589A (en) | 2017-12-22 |
| DK2989110T3 (en) | 2018-12-03 |
| PT2989110T (pt) | 2018-11-15 |
| GEP20186868B (en) | 2018-06-25 |
| HK1216317A1 (zh) | 2016-11-04 |
| WO2014173374A1 (en) | 2014-10-30 |
| MD20150117A2 (ro) | 2016-08-31 |
| UA116469C2 (uk) | 2018-03-26 |
| HRP20181872T1 (hr) | 2019-02-08 |
| US9896466B2 (en) | 2018-02-20 |
| EP2989110B1 (en) | 2018-08-08 |
| AU2014256546A1 (en) | 2015-11-12 |
| CN105452265B (zh) | 2017-05-10 |
| CA2909994A1 (en) | 2014-10-30 |
| SI2989110T1 (sl) | 2019-01-31 |
| CA2909994C (en) | 2018-06-26 |
| KR20150144756A (ko) | 2015-12-28 |
| EP2989110A1 (en) | 2016-03-02 |
| PL2989110T3 (pl) | 2019-03-29 |
| EA201591918A1 (ru) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120821T1 (el) | Παραγωγα ταμοξιφαινης για θεραπεια νεοπλασματικων ασθενειων, ειδικα με υψηλο επιπεδο πρωτεϊνης her2 | |
| CY1124404T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων | |
| CY1122340T1 (el) | Αντιπολλαπλασιαστικες ενωσεις και μεθοδοι χρησης αυτων | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| BR112019002275A2 (pt) | inibidores aminopirimidina de ssaos | |
| BR112018005307A2 (pt) | aditivo para conferir baixo acúmulo de calor a um componente de borracha | |
| CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1123154T1 (el) | Παραγοντας ενισχυσης της επιδρασης αποκαταστασης μετα απο νευρικη βλαβη που περιλαμβανει ενα παραγωγο αλκυλαιθερα ή ενα αλας αυτου | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| CY1119134T1 (el) | Υποδοχεις της νεπριλυσινης | |
| UY37900A (es) | Nuevos derivados de rapamicina | |
| MX2017014613A (es) | Compuestos de bencimidazol e imadazopiridin-carboximidamida que tienen actividad como inhibidores de indolamina 2,3-dioxigenasa. | |
| BR112018002499A2 (pt) | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica | |
| EA201890124A1 (ru) | Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| CY1117122T1 (el) | Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης | |
| CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| EA201790337A1 (ru) | Кристаллические формы ингибиторов глутаминазы | |
| CY1119677T1 (el) | Παραγωγα δολαστατινης 10 και αουριστατινων | |
| BR112016007396A2 (pt) | derivados de cetona pirídicos, método de preparação dos mesmos e aplicação farmacêutica dos mesmos | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| BR112016011016A8 (pt) | derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica. |